Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announced today that John Higgins, President and Chief Executive Officer of Ligand, will present at the JMP Securities 7th Annual Healthcare Conference
on Thursday, July 12, 2012 at 9:30 a.m. Eastern (6:30 a.m. Pacific Time). The conference takes place at the Peninsula hotel in New York.
A live webcast of the presentation will be available on the Company’s website
. A replay of the presentation will be archived on the site for 30 days.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., The Medicines Company, Curis, Inc. and Rib-X Pharmaceuticals. Please visit
for more information on Captisol. For more information on Ligand, please visit
Follow Ligand on Twitter @Ligand_LGND.